Synapse - Gynecologic Medicine Service

Results (2180)

Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

Meeting Abstract

Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Park, J. O.; Cassier, P. A.; Kamath, S. D.; Meng, D. T. W.; Dotan, E.; Kim, R.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)

Meeting Abstract

Kyi, C. K.; Spira, A.; Carbone, D. P.; Johnson, M. L.; Henick, B. S.; Johnson, B.; Borghaei, H.; Mahipal, A.; Hecht, J. R.; Catenacci, D.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results

Meeting Abstract

Gutierrez, M.; Friedman, C. F.; Long, G. V.; Ascierto, P. A.; Melero, I.; Richards, D.; Bastos, B. R.; Moreno Garcia, V.; Uemura, M.; Conkling, P.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study

Meeting Abstract

Colombo, N.; Van Gorp, T.; Matulonis, U. A.; Oaknin, A.; Grisham, R. N.; Fleming, G.; Olawaiye, A.; Tudor, I. C.; Pashova, H. I.; Lorusso, D.
Annals of Oncology (2022)

Fulltext@MSK | Save

Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor a (FR a)-positive cancer

Meeting Abstract

Matulonis, U. A.; Moore, K. N.; Lorusso, D.; Oaknin, A.; Pignata, S.; Denys, H.; Colombo, N.; Van Gorp, T.; Konner, J.; Romeo Marin, M.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor a (FRa)-positive cancer

Meeting Abstract

Moore, K. N.; Lorusso, D.; Oaknin, A.; Pignata, S.; Denys, H.; Colombo, N.; Van Gorp, T.; Konner, J.; Romeo Marin, M.; Harter, P.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial

Meeting Abstract

Friedman, C. F.; D'Souza, A. A.; Tinker, A. V.; Corral, E.; Gambardella, V.; Goldman, J. W.; Loi, S.; Melisko, M.; Oaknin, A.; Spanggaard, I.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

Meeting Abstract

Makker, V.; Colombo, N.; Herraez, A. C.; Monk, B. J.; Mackay, H.; Santin, A. D.; Miller, D. S.; Moore, R. G.; Baron-Hay, S. E.; Ray-Coquard, I. L.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety

Meeting Abstract

Gonzalez Martin, A. J.; Pothuri, B.; Vergote, I. B.; Graybill, W.; Mirza, M. R.; Mccormick, C.; Lorusso, D.; Freyer, G.; Backes, F.; Baumann, K. H.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)

Meeting Abstract

Moore, K. N.; Oza, A. M.; Colombo, N.; Oaknin, A.; Scambia, G.; Lorusso, D.; Banerjee, S.; Murphy, C.; Konner, J.; Lim, P.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save